why choose us

First received: May 18, 2023

Clinical Trial: Effect of Refnot on Immunity in Cancer Patients

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Solid Tumor

Study Type: INTERVENTIONAL


Official Title: Effect of Refnot on Immunity in Cancer Patients

Brief Summary: The study was planned to include disseminated patients with various solid tumors (melanoma, soft tissue sarcoma, breast cancer, colon cancer, etc.).The study drug was administered subcutaneously at a dose of 400,000 IU once a day, 3 times a week (every other day), for 4 weeks.In the absence of disease progression - an additional 4 weeks.

Read more